Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

The adoptive transfer of CD19-specific chimeric antigen receptor engineered T cells (CAR T cells) resulted in encouraging clinical trials in indolent B-cell malignancies. However, they also show the limitations of this fascinating technology: CAR T cells can lead to even life-threatening off-tumor,...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Cancer J
Prif Awduron: Cartellieri, M, Feldmann, A, Koristka, S, Arndt, C, Loff, S, Ehninger, A, von Bonin, M, Bejestani, E P, Ehninger, G, Bachmann, M P
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2016
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5022178/
https://ncbi.nlm.nih.gov/pubmed/27518241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2016.61
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg